These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 38254780)

  • 1. The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy.
    Feng H; Feng J; Han X; Ying Y; Lou W; Liu L; Zhang L
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Siglec Signaling in the Tumor Microenvironment.
    van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
    Front Immunol; 2021; 12():790317. PubMed ID: 34966391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment.
    van de Wall S; Santegoets KCM; van Houtum EJH; Büll C; Adema GJ
    Trends Immunol; 2020 Apr; 41(4):274-285. PubMed ID: 32139317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and expression of 3 siglecs-like in Oreochromis niloticus neutrophil, and their interaction with group B streptococcal sialylated capsular polysaccharides.
    Dong J; Wei Y; Ye X; Sun C; Tian Y; Lu M; Du J; Chen Z
    Mol Immunol; 2016 May; 73():158-69. PubMed ID: 26847490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of sialic acid diversity in cancer- and non-cancer related CA125 antigen using sialic acid-binding Ig-like lectins (Siglecs).
    Mitic N; Milutinovic B; Jankovic M
    Dis Markers; 2012; 32(3):187-94. PubMed ID: 22377735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensing the neuronal glycocalyx by glial sialic acid binding immunoglobulin-like lectins.
    Linnartz-Gerlach B; Mathews M; Neumann H
    Neuroscience; 2014 Sep; 275():113-24. PubMed ID: 24924144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
    Bärenwaldt A; Läubli H
    Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
    [No Abstract]   [Full Text] [Related]  

  • 8. Tools to study and target the Siglec-sialic acid axis in cancer.
    Läubli H; Kawanishi K; George Vazhappilly C; Matar R; Merheb M; Sarwar Siddiqui S
    FEBS J; 2021 Nov; 288(21):6206-6225. PubMed ID: 33251699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leishmania donovani Utilize Sialic Acids for Binding and Phagocytosis in the Macrophages through Selective Utilization of Siglecs and Impair the Innate Immune Arm.
    Roy S; Mandal C
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004904. PubMed ID: 27494323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9.
    Chan C; Lustig M; Jansen JHM; Garcia Villagrasa L; Raymakers L; Daamen LA; Valerius T; van Tetering G; Leusen JHW
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.
    Stanczak MA; Siddiqui SS; Trefny MP; Thommen DS; Boligan KF; von Gunten S; Tzankov A; Tietze L; Lardinois D; Heinzelmann-Schwarz V; von Bergwelt-Baildon M; Zhang W; Lenz HJ; Han Y; Amos CI; Syedbasha M; Egli A; Stenner F; Speiser DE; Varki A; Zippelius A; Läubli H
    J Clin Invest; 2018 Nov; 128(11):4912-4923. PubMed ID: 30130255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cloning, characterization, and phylogenetic analysis of siglec-9, a new member of the CD33-related group of siglecs. Evidence for co-evolution with sialic acid synthesis pathways.
    Angata T; Varki A
    J Biol Chem; 2000 Jul; 275(29):22127-35. PubMed ID: 10801860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sialylated glycoproteins as biomarkers and drivers of progression in prostate cancer.
    Wen R; Zhao H; Zhang D; Chiu CL; Brooks JD
    Carbohydr Res; 2022 Sep; 519():108598. PubMed ID: 35691122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sialic Acid-Siglec Axis in Human Immune Regulation, Involvement in Autoimmunity and Cancer and Potential Therapeutic Treatments.
    Gianchecchi E; Arena A; Fierabracci A
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment.
    Egan H; Treacy O; Lynch K; Leonard NA; O'Malley G; Reidy E; O'Neill A; Corry SM; De Veirman K; Vanderkerken K; Egan LJ; Ritter T; Hogan AM; Redmond K; Peng L; Che J; Gatlin W; Jayaraman P; Sheehan M; Canney A; Hynes SO; Kerr EM; Dunne PD; O'Dwyer ME; Ryan AE
    Cell Rep; 2023 May; 42(5):112475. PubMed ID: 37167967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential to target sialylation and SIGLECs in neurodegenerative and psychiatric diseases.
    Wißfeld J; Abou Assale T; Cuevas-Rios G; Liao H; Neumann H
    Front Neurol; 2024; 15():1330874. PubMed ID: 38529039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deacetylated sialic acids modulates immune mediated cytotoxicity via the sialic acid-Siglec pathway.
    Grabenstein S; Barnard KN; Anim M; Armoo A; Weichert WS; Bertozzi CR; Parrish CR; Willand-Charnley R
    Glycobiology; 2021 Nov; 31(10):1279-1294. PubMed ID: 34192335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells.
    Avril T; Floyd H; Lopez F; Vivier E; Crocker PR
    J Immunol; 2004 Dec; 173(11):6841-9. PubMed ID: 15557178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs.
    Läubli H; Alisson-Silva F; Stanczak MA; Siddiqui SS; Deng L; Verhagen A; Varki N; Varki A
    J Biol Chem; 2014 Nov; 289(48):33481-91. PubMed ID: 25320078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands.
    Boelaars K; van Kooyk Y
    Trends Cancer; 2024 Mar; 10(3):230-241. PubMed ID: 38160071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.